CD160+CD8+ T cells for improved immunotherapy



Summary

CD160+CD8+ T cells are a subset of cytotoxic T lymphocytes (CTLs) with enhanced antitumor activity. CD160, an activating receptor, distinguishes these cells and contributes to their superior functionality. Research indicates that CD160+CD8+ T cells exhibit increased cytokine production, enhanced cytotoxic killing of tumor cells, and improved infiltration into tumor tissues compared to their CD160- counterparts. Therefore, targeting and expanding these CD160+CD8+ T cells may represent a promising strategy for developing more effective cancer immunotherapies. Further research is aimed at understanding the mechanisms behind their enhanced function and optimizing their use in adoptive cell therapy and other immunotherapy approaches.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!